Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-04-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2022年限制性股票激励计划（草案）
Board/Management Information Classification · 95% confidence The document is a detailed plan regarding a 2022 restricted stock incentive plan for 科兴生物制药股份有限公司 (Kexing Biopharmaceutical Co., Ltd.). It includes legal references, detailed terms of the stock incentive plan, conditions for granting and vesting restricted stock, management and supervisory structures, and procedures for implementation. The content is focused on the company's stock incentive scheme for management and key employees, including the number of shares, pricing, vesting conditions, and governance related to the plan. This type of document is a detailed management or board-level information disclosure about changes in senior management incentives and equity compensation plans. It is not a financial report, earnings release, or regulatory filing about financial results. It is not a proxy statement or voting results announcement, but rather a detailed plan document. Therefore, the most appropriate classification is Board/Management Information (MANG), as it relates to management incentives and governance changes at the board level.
2022-04-27 Chinese
2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending March 31, 2022. The length of the document (12,272 characters) and the presence of comprehensive financial data confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-27 Chinese
关于召开2021年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of the company, including the date, voting methods, agenda items, and instructions for shareholders. It includes information about the meeting logistics, voting procedures, and proxy forms. The document does not contain the actual annual report or financial statements but rather the announcement and materials related to the AGM itself. The document length is 4428 characters, which is relatively short and consistent with an AGM notice rather than a full annual report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-04-27 Chinese
科兴生物制药股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 科兴生物制药股份有限公司 dated April 2022. It contains detailed provisions about the company's organization, shareholder rights, board structure, management, capital, and governance rules. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is a comprehensive governance document that sets out the internal rules and structure of the company rather than financial results, audit opinions, or meeting announcements. It is not an announcement or a report of a meeting, nor a financial report or earnings release. Therefore, the document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-04-27 Chinese
2022年限制性股票激励计划（草案）摘要公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding a 2022 restricted stock incentive plan (股权激励计划) for a company, including specifics on stock grants, eligibility, conditions, pricing, vesting, and legal compliance. It discusses the issuance of shares to employees and management as part of a stock incentive program. This type of document is related to executive and employee compensation plans involving equity awards. It is not a financial report, earnings release, or regulatory filing about financial results. It is also not a proxy statement or voting results announcement. The content fits best with Remuneration Information filings, which cover compensation plans and equity incentive schemes for executives and employees. Therefore, the appropriate classification is DEF 14A (Remuneration Information). The document length and detail confirm it is the plan itself, not just an announcement of a report, so it is not RPA or RNS.
2022-04-27 Chinese
关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a public announcement by an independent director of a company (科兴生物制药股份有限公司) soliciting proxy voting rights from shareholders for the upcoming 2021 Annual General Meeting (AGM) scheduled on May 19, 2022. It details the process, timeline, and conditions for shareholders to delegate their voting rights to the independent director for specific agenda items related to a restricted stock incentive plan. The document does not contain financial statements or results but is focused on the solicitation of proxy votes for the AGM. It is not the AGM materials themselves but an announcement related to proxy solicitation for the AGM. Therefore, the document fits best under the category of Proxy Solicitation & Information Statement (PSI). The document length is 4330 characters, which is consistent with a detailed announcement but not a full report or presentation.
2022-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.